Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Yutaro
Y
Suzuki
Takuro
T
Sugai
Naoki
N
Fukui
Junzo
J
Watanabe
Shin
S
Ono
Nobuto
N
Tsuneyama
Mami
M
Saito
Toshiyuki
T
Someya
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006706:Homeostasis; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D055105:Waist Circumference / Q000187:drug effects*; D015431:Weight Loss / Q000187:drug effects*; D055815:Young Adult
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D010880:Piperidines; D000069348:Quetiapine Fumarate; C079310:blonanserin